Abdominal sepsis is the key market.... EUPHAS2 confirms an overall mortality reduction when compared to the population conventionally treated (epidemiological studies)
Patients with abdominal SS are effectively treated with results identical to those of the original EUPHAS trial.
Non abdominal patient do not show a similar benefit, however data suggests that EAA could help in patient selection